These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 421199)

  • 1. Efficacy of tumor cell extracts in immunotherapy of murine EL-4 leukemia.
    Cantrell JL; McLaughlin CA; Ribi E
    Cancer Res; 1979 Apr; 39(4):1159-67. PubMed ID: 421199
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of in vivo model murine tumor destruction by combined immunoradiotherapy.
    Johnson TS
    Cancer Res; 1978 May; 38(5):1388-97. PubMed ID: 76513
    [No Abstract]   [Full Text] [Related]  

  • 3. Serologic analysis of tumor-associated surface antigens on a Moloney leukemia virus-induced lymphoma, MBL-2.
    Ng AK; McIntire R; Holden HT; Herberman RB
    J Immunol; 1978 Sep; 121(3):856-62. PubMed ID: 690439
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of inoculation with neuraminidase-treated tumor cells on macrophage cytotoxicity in vitro.
    Alley CD; Snodgrass MJ
    Cancer Res; 1978 Aug; 38(8):2332-8. PubMed ID: 667829
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibition of the effect of immunocytotherapy in leukemia in mice under stress and the possibilities of its withdrawal].
    Sukhikh GT
    Biull Eksp Biol Med; 1984 Dec; 98(12):694-6. PubMed ID: 6542442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of immunity to murine leukemia (LSTRA) by Bacillus Calmette-Guérin.
    Bartlett GL; Kreider JW; Purnell DM
    Cancer Res; 1978 Dec; 38(12):4401-8. PubMed ID: 719627
    [No Abstract]   [Full Text] [Related]  

  • 7. H-2 restriction of adoptive immunotherapy of advanced tumors.
    Greenberg PD; Cheever MA; Fefer A
    J Immunol; 1981 Jun; 126(6):2100-3. PubMed ID: 6453154
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
    Cheever MA; Kempf RA; Fefer A
    J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoreactive cells in cancer-active immunotherapy: their cytotoxic potential and genetic restriction.
    Olsson L; Kiger N; Mathe G
    Transplant Proc; 1980 Mar; 12(1):167-71. PubMed ID: 7368287
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
    J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H-2-restricted cytolytic T lymphocytes specific for a subclass of AKR endogenous leukemia virus-induced tumors: correlation of tumor cell susceptibility with expression of the gross cell surface antigen.
    Green WR
    J Immunol; 1980 Dec; 125(6):2584-90. PubMed ID: 6159413
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship of expression of A cell-surface antigen on activated murine macrophages to tumor cell cytotoxicity.
    Kaplan AM; Bear HD; Kirk L; Cummins C; Mohanakumar T
    J Immunol; 1978 Jun; 120(6):2080-5. PubMed ID: 659893
    [No Abstract]   [Full Text] [Related]  

  • 13. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
    J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressed development of cytotoxic lymphoid cells in tumor-immunized mice.
    Martin WJ; Wunderlich JR; Macdonald J
    Isr J Med Sci; 1973 Mar; 9(3):324-31. PubMed ID: 4710040
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
    Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
    J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells.
    Benjamini E; Fong S; Erickson C; Leung CY; Rennick D; Scibienski RJ
    J Immunol; 1977 Feb; 118(2):685-93. PubMed ID: 839074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
    Matis LA; Shu S; Groves ES; Zinn S; Chou T; Kruisbeek AM; Rosenstein M; Rosenberg SA
    J Immunol; 1986 May; 136(9):3496-501. PubMed ID: 2420893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of success in classical immunotherapy to the relative immunorejective strength of the tumor.
    Reif AE
    J Natl Cancer Inst; 1986 Oct; 77(4):899-908. PubMed ID: 3020300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated immunity to Friend virus-induced leukemia.
    Ting CC; Shiu G; Rodrigues D; Herberman RB
    Cancer Res; 1974 Jul; 34(7):1684-7. PubMed ID: 4134674
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor induction by immunologically activated murine leukemia virus: cellular immunity early in the graft-vs-host reaction.
    Ruddle NH; Armstrong MY; Richards FF
    J Immunol; 1974 Feb; 112(2):706-15. PubMed ID: 4149884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.